Monday, 21 October 2019

Boehringer Ingelheim puts focus on novel therapies for retinal diseases

24 September 2019 | News

Partners with Inflammasome Therapeutics

Image credit- istock.com

Image credit- istock.com

German player Boehringer Ingelheim and US based Inflammasome Therapeutics Inc. (Inflammasome) have announced that they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases.

By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases.

Boehringer Ingelheim takes a holistic approach in the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. The company has built a comprehensive pipeline portfolio of next generation therapy approaches in various stages of development up to Phase 2 in macular degeneration, diabetic retinal diseases and beyond. Inflammasome’s novel delivery technology using a long-acting degradable IVT implant complements this portfolio.

Inflammasome is entitled to receive up to $160 million in up-front, research and development support and milestone gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account